Tenax Therapeutics Inc
Research Tenax Therapeutics Inc (TENX) on Bullrun: market cap USD 74.12M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerTENX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 74.12M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 17.80M
- Free cash flow-USD 14.15M
Valuation Snapshot
latest market cap is USD 74.12M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 52.60M | -USD 35.80M | n/a | -1.34 | USD 97.60M | n/a | USD 97.07M |
| FY2024 | USD 0 | -USD 17.60M | -USD 14.81M | n/a | -1.15 | USD 94.90M | USD 278.80K | USD 91.99M |
| FY2023 | n/a | -USD 7.70M | -USD 5.90M | n/a | -31.04 | USD 9.80M | USD 501.00K | USD 8.10M |
| FY2022 | n/a | USD 11.05M | -USD 11.39M | n/a | n/a | USD 2.12M | USD 330.91K | USD 1.49M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 74.12M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 113.54M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 21.18M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 6.56M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 4.96M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 26.29M | n/a | n/a | n/a |
About Tenax Therapeutics Inc
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Tenax Therapeutics Inc's market cap?
Tenax Therapeutics Inc's market capitalization is USD 74.12M.
What does Tenax Therapeutics Inc do?
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc.